The Johnson & Johnson vaccine doesn’t require a booster shot, circumventing the two-dose problems posed by its competitors. The company plans to seek FDA approval in early February. | AaronP/Bauer-Griffin/GC Images/Getty Images
The FDA could make an emergency use authorization as soon as this weekend, paving the way for distribution.
A panel of expert advisers to the Food and Drug Administration (FDA) voted unanimously on Friday afternoon to recommend the one-dose Covid-19 vaccine developed by Johnson & Johnson for an emergency use authorization. The next step is for the FDA to accept the recommendation, which could happen as soon as this weekend, clearing the way for distribution.
Earlier this week, the FDA posted a briefing going over the results of the phase 3 clinical trials of the Johnson & Johnson vaccine, which included 40,000 participants in several countries divided randomly into